Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.

Romain Cohen Gilles ManceauJack FiskumGreg YothersRichard M Goldberg Takayuki Yoshino Steven R AlbertsCarmen AllegraAimery de GramontJean-Francois SeitzMichael O'ConnellDaniel HallerNorman WolmarkCharles ErlichmanAlberto ZaniboniSara LonardiRachel KerrAxel GrotheyFrank A Sinicrope Thierry André Qian Shi

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)

Adding oxaliplatin to FP improves OS and DFS in patients with MSI stage III CC. Compared with MSS, MSI patients experienced better outcomes in the N1 group but similar survival in the N2 group.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
early stage
prognostic factors
type diabetes
patient reported outcomes
metabolic syndrome
skeletal muscle
phase iii